Biomarker based prognostic models including the Glasgow Prognostic Score (GPS) and its modification (mGPS), based on CRP as a marker of systemic inflammation and albumin as an indicator of malnutrition, have been validated in various oncological settings, including lung cancer and patients with advanced NSCLC [39,40,41]. This evidence concerns the gene ALB and nutritional deficiency disease.